2009
Best Doctors
New York Magazine

Risk factors for chronic kidney disease

Expertise in the design of clinical trails is used to understand the clinical epidemiology and treatment of HIV-associated kidney disease. Other areas of clinical research include risk factors for cardiovascular disease in chronic kidney disease, outcomes in endstage renal disease and the prevalence and natural history of renal artery stenosis.

Clinical Trials

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease
The purpose of this study is to evaluate whether finerenone is effective and safe in treating patients with type 2 diabetes mellitus and Diabetic Kidney Disease (DKD) in addition to regular therapy. The study is considered research because the study drug finerenone is under devel...

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care
The purpose of this study is to evaluate whether finerenone is effective and safe in treating patients with type 2 diabetes mellitus and Diabetic Kidney Disease (DKD) in addition to regular therapy.   The study is considered research because the study drug finerenone is u...

Winston JA, Burns GC, Klotman PE. Treatment of HIV-associated nephropathy. Semin Nephrol 2000; 20(3): 293-298.

Bruggeman LA, Ross MD, Tanji N, Cara S, Dikman RE, Gordon GC, Burns VD, D'Agati JA, Winston JA, Klotman ME, Klotman PE. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000; 11(11): 2079-2087.

Ross MJ, Klotman PE, Winston JA. HIV-associated nephropathy: case study and review of the literature. AIDS Patient Care STDS 2000; 14(12): 637-645.

Winston J, Bruggeman LA, Ross MD, Jacobson J, Ross L, D'Agati VD, Klotman PE, Klotman ME. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001; 344(26): 1979-1984.

Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Brodie S, Stacy CB, Mehta D, Parsons R, Norton K, O'Callaghan M, Desnick RJ. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001; 68(3): 711-722.

Winston JA. Editorial comment: The increasing problem of HIV-Associated Nephropathy. AIDS Reader 2002 12:110-111.

Schwartz EJ, Neumann AU, Fierer DS, Keller MJ, Parkas V, Zhang DY, Klotman ME, Winston JA, Klotman PE. HIV-1 dynamics in haemodialysis patients. AIDS 2002; 14: 1301-1303.

Winston JA, Klotman PE. Renal Disease. In: Dolin R, Masur H, Saag M, editors. AIDS Therapy. 2nd New York, Churchill Livingston; 2003.

Szczech LA, Kalayjian R, Rodriguez R, Gupta S, Coladonato J, Winston J. The clinical characteristics and antiretroviral dosing patterns of HIV-infected patients receiving dialysis. Kidney Int 2003 Jun; 63(6): 2295-2300.

Farkouh ME, Robbins MJ, Urooj-Zafar M, Shimbo D, Davidson KW, Puttappa R, Winston J, Halperin JL, Epstein EM, Patel M, Talor Z, Chesebro JH. Association between troponin I levels and mortality in stable hemodialysis patients. Am J Med 2003 February; 114(3): 224-226.